Skip to main content

Table 1 Inhibitory compounds as anti-tubercular agents

From: Computational investigation, virtual docking simulation of 1, 2, 4-Triazole analogues and insillico design of new proposed agents against protein target (3IFZ) binding domain

S/N

Molecules

Experimental activity (pBA)

Predicted activity (pBA)

Residual

Leverage

1a

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(tert-butyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

5.7268

6.0896

− 0.3628

0.1619

2

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(4-nitrophenyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

5.5023

5.3625

0.1398

0.2423

3a

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(4-methoxyphenyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

6.007

6.3186

− 0.3116

0.1304

4a

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(4-chlorophenyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

5.0064

5.5561

− 0.5497

0.3033

5a

3-(allylthio)-1H-1,2,4-triazole

5.7317

5.6841

0.0476

0.0303

6

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-(tert-butyl)-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-1,2,3-triazole

5.6376

5.5557

0.0819

0.3826

7

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-1,2,3-triazole

4.7441

5.1002

− 0.3561

0.3538

8

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-(4-chlorophenyl)-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-1,2,3-triazole

6.1674

5.9575

0.2099

0.0601

9a

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

6.3713

6.9926

− 0.6213

0.3184

10

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

7.4134

7.2209

0.1925

0.0598

11

5-(4-nitrophenyl)-3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

5.7441

6.3581

− 0.614

0.0714

12

5-(4-methoxyphenyl)-3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

5.9258

6.0358

− 0.11

0.0424

13

5-(4-chlorophenyl)-3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

7.5281

7.0701

0.458

0.0762

14

1-allyl-3-(tert-butyl)-5-(prop-2-yn-1-ylthio)-1H-1,2,4-triazole

6.3793

6.2871

0.0922

0.1938

15a

1-allyl-5-(tert-butyl)-3-(prop-2-yn-1-ylthio)-1H-1,2,4-triazole

8.0615

7.5772

0.4843

0.0658

16

5-(allylthio)-3-methyl-1H-1,2,4-triazole

7.8807

7.7668

0.1139

0.0504

17

5-(allylthio)-3-(tert-butyl)-1H-1,2,4-triazole

6.4171

6.4769

− 0.0598

0.1296

18

5-(allylthio)-3-(4-nitrophenyl)-1H-1,2,4-triazole

5.9471

6.443

− 0.4959

0.0347

19

3-(allylthio)-5-(4-chlorophenyl)-1H-1,2,4-triazole

8.0899

7.7759

0.314

0.1757

20

3-(allylthio)-5-(4-methoxyphenyl)-1H-1,2,4-triazole

7.6397

7.7175

− 0.0778

0.3321

21

1-allyl-3-(allylthio)-1H-1,2,4-triazole

6.3981

5.9875

0.4106

0.4076

22

1-allyl-3-(allylthio)-5-methyl-1H-1,2,4-triazole

5.8131

6.3817

− 0.5686

0.2386

23

1-allyl-3-(allylthio)-5-(tert-butyl)-1H-1,2,4-triazole

6.2878

6.2104

0.0774

0.2302

24a

1-allyl-3-(allylthio)-5-(4-nitrophenyl)-1H-1,2,4-triazole

8.0615

7.703

0.3585

0.2547

25

1-allyl-3-(allylthio)-5-(4-methoxyphenyl)-1H-1,2,4-triazole

7.366

6.8935

0.4725

0.3849

26

1-allyl-3-(allylthio)-5-(4-chlorophenyl)-1H-1,2,4-triazole

7.659

6.844

0.815

0.232

27a

1-allyl-5-(allylthio)-1H-1,2,4-triazole

7.9432

7.7982

0.145

0.0307

28a

1-allyl-5-(allylthio)-3-methyl-1H-1,2,4-triazole

7.9759

8.6181

− 0.6422

0.4921

29a

1-allyl-5-(allylthio)-3-(tert-butyl)-1H-1,2,4-triazole

5.2717

7.6208

− 2.3491

0.3163

30

1-allyl-5-(allylthio)-3-(4-nitrophenyl)-1H-1,2,4-triazole

6.304

6.0214

0.2826

0.1944

31

1-allyl-5-(allylthio)-3-(4-methoxyphenyl)-1H-1,2,4-triazole

7.3233

7.1344

0.1889

0.4957

32

1-allyl-5-(allylthio)-3-(4-chlorophenyl)-1H-1,2,4-triazole

6.0097

6.995

− 0.9853

0.0482

33a

3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

5.5994

5.735

− 0.1356

0.095

34a

5-methyl-3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

4.9074

5.7514

− 0.844

0.1017

35

5-(tert-butyl)-3-(prop-2-yn-1-ylsulfonyl)-1H-1,2,4-triazole

6.8568

6.9247

− 0.0679

0.178

36

1-benzyl-4-(((3-methyl-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

7.8456

7.1946

0.651

0.0981

37

4-(((1H-1,2,4-triazol-5-yl)thio)methyl)-1-benzyl-1H-1,2,3-triazole

7.3079

7.9753

− 0.6674

0.0334

38

1-benzyl-4-(((3-(tert-butyl)-1H-1,2,4-triazol-5-yl)thio)methyl)-1H-1,2,3-triazole

7.314

7.7043

− 0.3903

0.7119

39

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-1,2,3-triazole

6.8719

7.1271

− 0.2552

0.2365

40

1-benzyl-4-(((1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-methyl-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-1,2,3-triazole

7.9759

7.7716

0.2043

0.6105

  1. Superscript “a” represents the test set. The calculated activity (pA) is generated using the QSAR model built in this study. The residual values are the difference between the observed activity (pA) and calculated activity (pA). Leverage value for each compound represents the diagonal element of the hat matrix which defines the applicability domain space of the each compound